Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Idiopathic Pulmonary Fibrosis Clinical Trials

A listing of Idiopathic Pulmonary Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (69) clinical trials

Mechanisms of Familial Pulmonary Fibrosis

Potential research subjects will be sent a questionnaire (modified version of the ATS-DLD-78 questionnaire) and study consent form. Individuals with no prior history of lung disease and a dyspnea score of 2 or less will be offered the opportunity to undergo further research evaluation, which will include HRCT scanning, pulmonary ...

Phase N/A

Detection of Early Idiopathic Pulmonary Fibrosis

The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Phase N/A

Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

Multi-center, non-interventional, prospective cohort study aiming to enroll 120 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Phase N/A

Quality of Life in IPF - Patient and Physician Perceptions

Idiopathic Pulmonary Fibrosis is a progressive and debilitating disease characterized by progressive scarring of the lung parenchyma of unknown cause. In the US approximately 100,000 individuals have been diagnosed with this disease and the only cure available is lung transplantation. There have been two drugs approved by the FDA for ...

Phase N/A

Korean Idiopathic Pulmonary Fibrosis Registry

Korean ILD Study Group includes investigators of 30 hospitals. Demographic, pulmonary function, laboratory data, chest CT findings and hospital course of IPF patients are collected.

Phase N/A

Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis

Fibroproliferative diseases are the cause of 45% of deaths in developed countries. A wide range of diseases belongs to this category, including pulmonary fibrosis. The fact that in some fibroproliferative diseases the fibrotic process may involve several organs suggests the activation of common causative and pathophysiological mechanisms, which involve inflammatory ...

Phase N/A

Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients

Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disease characterized by a progressive and irreversible deterioration in respiratory function, resulting in impaired quality of life (QoL) and patient dependence. The factors involved in the alteration of QoL in these patients are the physical symptoms related to fibrosis (dyspnea, cough, fatigue) ...

Phase N/A

Effects of Inpatient Pulmonary Rehabilitation on Frailty in Patients After Lung-Transplantation

Rationale Frailty is a complex clinical syndrome describing a loss of physical and/or cognitive functionality which leads to a decreased resistance to stressors such as operations or illness. It is associated with increased number of falls, exacerbations, adverse health outcomes and a higher mortality (7-10). Frail LTx-candidates have a higher ...

Phase N/A

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

Interstitial lung diseases (ILD) are a group of chronic, progressive lung disorders. The most common ILD is idiopathic pulmonary fibrosis (IPF) with a average survival ranging between 2.5-5 years after diagnosis. The term pulmonary fibrosis means scarring of the lung tissue and is the cause of worsening shortness of breath. ...

Phase N/A